TLR4 is a regulator of trained immunity in a murine model of Duchenne muscular dystrophy

Salyan Bhattarai1,2, Qian Li1,2, Jun Ding1,2, Feng Liang1,2, Ekaterina Gusev1,2, Orsolya Lapohos1,2, Gregory J. Fonseca1,2, Eva Kaufmann1,2, Maziar Divangahi1,2,3 & Basil J. Petrof1,2✉

Dysregulation of the balance between pro-inflammatory and anti-inflammatory macrophages has a key function in the pathogenesis of Duchenne muscular dystrophy (DMD), a fatal genetic disease. We postulate that an evolutionarily ancient protective mechanism against infection, known as trained immunity, drives pathological inflammation in DMD. Here we show that bone marrow-derived macrophages from a murine model of DMD (mdx) exhibit cardinal features of trained immunity, consisting of transcriptional hyperresponsiveness associated with metabolic and epigenetic remodeling. The hyperresponsive phenotype is transmissible by bone marrow transplantation to previously healthy mice and persists for up to 11 weeks post-transplant. Mechanistically, training is induced by muscle extract in vitro. The functional and epigenetic changes in bone marrow-derived macrophages from dystrophic mice are TLR4-dependent. Adoptive transfer experiments further support the TLR4-dependence of trained macrophages homing to damaged muscles from the bone marrow. Collectively, this suggests that a TLR4-regulated, memory-like capacity of innate immunity induced at the level of the bone marrow promotes dysregulated inflammation in DMD.
Duchenne muscular dystrophy (DMD) is one of the most frequent X-linked lethal disorders, affecting approximately 1 in 5000 males. Despite recent advances in cell- and gene-based therapies, DMD remains a devastating disease for which treatment options are extremely limited. The primary cause of the disease is loss of dystrophin, a large protein which helps link the internal cytoskeleton to the extracellular matrix of muscle cells, thereby providing mechanical stability to the muscle fiber membrane. Evidence from both animal models and humans indicates that maladaptive inflammatory mechanisms play an integral role in promoting the disease from its earliest stages.

Macrophages are the most abundant leukocyte population in DMD muscles, where their abnormal persistence and dysregulated production of inflammatory mediators play a key role in driving disease progression. In previous work, we generated dystrophin-deficient mdx mice (model of DMD) lacking the chemokine receptor CCR2 and demonstrated the importance of bone marrow (monocyte)-derived macrophages (BMDM) in early pathogenesis of the disease. Genetic abrogation of CCR2, which impairs the ability of inflammatory monocytes to exit the bone marrow, resulted in reduced numbers of pro-inflammatory macrophages in the dystrophic muscles, accompanied by reduced fibrosis and improved force generation. Intriguingly, genetic ablation of Toll-like receptor 4 (TLR4) in mdx mice led to similar beneficial effects along with a skewing of intramuscular macrophages toward a more anti-inflammatory profile. However, the cellular mechanisms underlying these phenomena are incompletely understood.

It is well established that macrophages have a large capacity to respond and adapt their function to different environmental cues. This plasticity is exemplified by the fact that in vitro stimulation with either interferon-γ (IFN-γ) or interleukin-4 (IL-4) can polarize the cells toward opposing phenotypes with pro-inflammatory (also called classically activated or M1-like) or anti-inflammatory (alternatively activated or M2-like) profiles, respectively. Moreover, it is well recognized that the above macrophage polarization model greatly oversimplifies and underestimates the true diversity of macrophage phenotypic states, particularly during chronic inflammation in vivo. Macrophage phenotype is also modulated by exposure to various pathogen-associated molecular patterns (PAMPs) and endogenous molecules released after tissue injury (damage-associated molecular patterns, or DAMPs), which can serve as ligands for pattern recognition receptors such as TLRs and NOD-like receptors involved in the regulation of trained immunity in monocytes/macrophages. In DMD local immune cell stimulation by DAMPs within the damaged muscles is thought to be a major contributor to disease progression, but the question of whether DAMPs or other factors released from dystrophic muscles might also induce wider epigenetic and functional changes at the level of myeloid cells within the bone marrow, has not been explored.

Here, we show major remodeling of the epigenetic, metabolic and functional inflammatory profiles of monocyte-derived macrophages from the bone marrow of mdx mice. The fact that these changes are found at a distance from the pathological muscle microenvironment implies a role for systemically released mediators such as DAMPs in driving the altered phenotype of these cells. In support of the latter mechanism, we find that abnormal epigenetic and functional characteristics of BMDM from muscular dystrophy mice are TLR4-dependent. Furthermore, the altered phenotype of mdx BMDM demonstrates the hallmark features of trained immunity, including being transmissible and long-lasting after bone marrow transplantation to non-dystrophic mice. Accordingly, trained immunity may be an important mechanism underlying both the generation and maintenance of pathological inflammation in DMD.

Results

mdx BMDM exhibit disease stage-specific alterations in basal inflammatory and metabolic profile. The BMDM from dystrophic mdx mice and age-matched wild-type (WT) controls were studied following 7 days in culture under basal conditions. To determine the influence of disease stage on BMDM phenotype, the cells were harvested at different ages, taking advantage of the fact that skeletal muscle pathology in mdx mice can be separated into prenecrotic (2–3 weeks old), necrotic (6–8 weeks old), and fibrotic (50–60 weeks old) stages of the disease. We first surveyed a panel of classical pro-inflammatory “M1” (iNOS, TNF, IL6, IL12a) and anti-inflammatory “M2” (TGFβ, CD206, Ym1, Arg1) macrophage marker genes in BMDM at the transcriptional level (Fig. 1a–c). During the prenecrotic phase, the expression of these genes was generally equivalent to WT. In contrast, there was significant basal upregulation of multiple pro-inflammatory as well as anti-inflammatory genes in mdx BMDM during the necrotic phase, most of which remained elevated to a lesser extent at the later fibrotic stage. These data indicate that in temporal association with the onset of dystrophic skeletal muscle pathology, the precursor cells in the bone marrow which give rise to macrophages are functionally modified.

To explore potential alterations in inflammatory signaling, we determined the levels of phosphorylated Signal Transducer and Activator of Transcription (STAT) proteins (Fig. 1d–f), which are known to be key players in canonical intracellular pathways linked to macrophage plasticity. Both p-STAT1 and p-STAT3 were unaltered in mdx BMDM during the prenecrotic phase, consistent with the M1 and M2 marker gene expression data. However, at the necrotic stage of disease there was exaggerated phosphorylation of STAT1 and STAT3 in mdx BMDM, which was mitigated but still present during the fibrotic phase. On the other hand, p-STAT6 was not detectable in mdx BMDM during either the necrotic or fibrotic stages (Supplementary Fig. 1). To investigate whether the changes in mdx BMDM phenotype include signs of metabolic reprogramming, we first assessed mitochondrial oxygen consumption rate (OCR) in BMDM. There were no significant differences in OCR between WT and mdx BMDM during the prenecrotic phase (Fig. 2a). However, significant reductions in both basal and maximal OCR were observed in mdx BMDM during the necrotic phase in comparison to the age-matched WT group (Fig. 2b). In contrast,
mdx BMDM from the fibrotic phase showed a reversal of this pattern with increased maximal OCR relative to age-matched WT values (Fig. 2c). Along the same lines, there were no significant differences in culture media lactate concentrations (index of glycolysis) between WT and mdx BMDM during the prenecrotic phase, whereas in older mice lactate was increased during the necrotic phase and decreased during the fibrotic phase in the mdx groups (Fig. 2d). Interestingly, in WT mice the induction of massive muscle necrosis by bilateral hindlimb muscle (tibialis anterior) injection of the myotoxic agent cardiotoxin in vivo did not trigger comparable alterations in either the inflammatory (Fig. 2e) or metabolic (Fig. 2f) profiles of BMDM. Repeated bouts of acute cardiotoxin-induced muscle damage were similarly unable to recapitulate the BMDM phenotype of mdx mice (Fig. 2e). These results imply that chronic ongoing muscle injury is required to induce the abnormal immunometabolic phenotype observed in mdx BMDM.

mdx BMDM respond in an exaggerated fashion to heterologous inflammatory stimuli. We wished to determine whether mdx BMDM exhibit non-specific amplification of gene transcription responses after exposure to heterologous stimuli, which is a defining feature of trained immunity. For this purpose, we employed a variety of unrelated secondary stimuli (cytokines, PAMPs/DAMPs). Following acute exposure to the classical M1-polarizing stimulus of LPS + IFN-γ, mdx BMDM from the necrotic phase showed increased pro-inflammatory gene (iNOS, TNF, IL6, IL12α) transcript upregulation compared to WT BMDM (Fig. 3a). Greater anti-inflammatory gene expression (TGFβ, CD206, Ym1, Arg1) was similarly observed in mdx BMDM after exposure to the M2-polarizing cytokine IL-4 (Fig. 3b). Stimulation with fibrinogen, an endogenous TLR4 ligand DAMP previously implicated in DMD pathogenesis31, also triggered greater pro-inflammatory (Fig. 3c) as well as anti-inflammatory (Fig. 3d) gene transcript levels in the mdx BMDM.
Fig. 2 Metabolic changes in mdx BMDM at different disease stages. a–c Oxygen consumption rate (OCR) values after sequential treatment of BMDM with oligomycin (O), FCCP (F) and antimycin + rotenone (A/R) as measured by the Seahorse XF Analyzer: a prenecrotic (n = 8/group), b necrotic (n = 8/group), and c fibrotic (n = 8/group) phases of disease. OCR values are normalized to cell count. d Lactate levels (normalized to µg of cell lysate protein) in supernatants from WT and mdx BMDM after incubating the cells for 48 h in phenol-red-free RPMI culture media (n = 4/group for prenecrotic, n = 10/group for necrotic, and n = 5/group for fibrotic). e mRNA transcript levels in BMDM (expressed relative to the mean uninjured level represented by the dashed line) obtained from WT mice after acute muscle injury (Injury 1x = injection of cardiotoxin into both tibialis anterior muscles with euthanasia 3 days later; Injury 2x = injection of cardiotoxin into tibialis anterior and gastrocnemius muscles on days 0 and 3, respectively, with euthanasia at day 13) (n = 5/group). f Representative OCR curve from Injury 1x group in e (n = 5/group). Data represent means ± SEM of biologically independent samples from different mice. *P < 0.05 vs. WT (unpaired t-test, two-tailed). See Source Data file for the exact P-values.

Fig. 3 mdx BMDM exhibit non-specific amplification of M1 and M2 marker gene expression in response to heterologous stimuli. a–f BMDM from age-matched WT and mdx mice at the necrotic phase of disease were exposed to: a LPS + IFNγ (n = 5/group), b IL4 (n = 5/group), c, d fibrinogen (n = 3/group), or e, f β-glucan for 4 and 24 h (n = 5/group); mRNA transcript data for prototypical M1 and M2 marker genes are expressed relative to the mean basal WT (unstimulated) level determined on the same PCR plate. Data represent means ± SEM of biologically independent samples from different mice. *P < 0.05 vs. unstimulated WT and †P < 0.05 vs. stimulated WT at a given time point (one-way ANOVA followed by Tukey post-hoc test, two-tailed). See Source Data file for the exact P-values.
group. Furthermore, we exposed BMDM to the fungal cell wall-derived PAMP β-glucan, as a non-specific secondary stimulus which is entirely unrelated to DMD pathogenesis. Once again, significant hyperresponsiveness was observed in mdx BMDM relative to the WT group for β-glucan (Fig. 3e, f). An analogous but less pronounced pattern of generalized hyperresponsiveness to these stimuli was also found in mdx BMDM from the fibrotic phase of the disease (Supplementary Fig. 2). On the other hand, BMDM from prenecro tic mdx mice (Supplementary Fig. 3a–c) as well as cardiotoxin-injured mice (Supplementary Fig. 3d, e) failed to exhibit similarly amplified responses to secondary stimuli in comparison to WT BMDM. These data show that following the onset of chronic generalized skeletal muscle necrosis in mdx mice, BMDM are profoundly altered and demonstrate significant hyperresponsiveness to multiple forms of unrelated inflammatory stimuli.

**Sustained phenotypic reprogramming of mdx BMDM.** To account for the altered BMDM phenotype observed in post-necrotic mdx mice, we postulated that DAMPs released into the systemic circulation from widespread muscle damage could be at least partly responsible for these changes. To test this hypothesis, naive WT BMDM were first exposed to crushed skeletal muscle extract (ME) derived from either WT or mdx mice to act as a primary training stimulus; the ME was removed after 24 h, and the BMDM were then exposed 5 days later to fibrinogen acting as a secondary stimulus (Fig. 4a). For the majority of genes showing enhanced upregulation after the first challenge with ME, expression had largely returned to baseline levels prior to the secondary challenge with fibrinogen (Supplementary Fig. 4a, b). In comparison to the control BMDM (PBS group), the BMDM exposed to either WT-ME or mdx-ME demonstrated greater pro-inflammatory (Fig. 4b) as well as anti-inflammatory (Fig. 4c) gene upregulation in response to fibrinogen. Thus, exposing naive WT BMDM to components of damaged skeletal muscle induced a phenotype resembling the mdx BMDM. The magnitude of this effect was dependent on both the concentration (Supplementary Fig. 4c) and duration (Supplementary Fig. 4d) of exposure to ME, which could account for the fact that mdx serum induced lesser effects than the highest dose of ME (Supplementary Fig. 2). Overall, these findings support the concept that muscle damage-related molecules could potentially act as a primary “training stimulus” for the induction of trained immunity in BMDM of mdx mice.

To build on the above in vitro evidence for trained immunity, we next performed in vivo experiments whereby irradiated WT host mice received bone marrow transplants from either WT (WT→WT) or mdx (mdx→WT) donor mice (Fig. 4d). At 11 weeks after bone marrow reconstitution, there was no pathological macrophage infiltration in muscles of the WT host mice that received mdx donor BMDM (Supplementary Fig. 4f). However, the significant functional differences between WT and mdx origin BMDM remained intact when these cells were studied in vitro. Hence mdx origin BMDM continued to show greater pro- and anti-inflammatory gene responses after stimulation with fibrinogen (Fig. 4c, f) or β-glucan (Fig. 4g, h) despite being transplanted into WT mice. This in vivo transmissibility and long-term maintenance of the hyperresponsive mdx BMDM phenotype within a non-dystrophic WT host environment is consistent with the presence of innate immune memory.

**Phenotypic reprogramming of mdx BMDM is TLR4-dependent.** TLR4 has the ability to sense a wide range of DAMPs released after tissue injury. Therefore, we generated mdx mice with genetic abrogation of TLR4 (mdxTLR4−/−) to determine the role of TLR4 in the altered immunophenotype of mdx BMDM. Under basal conditions mdxTLR4−/− BMDM exhibited lower transcript levels of both pro- and anti-inflammatory genes compared to mdx BMDM, most strikingly during the necrotic stage of the disease (Fig. 5a). In this regard, unsupervised hierarchical clustering (Fig. 5b) clearly separated mdx from WT and mdxTLR4−/− BMDM during the necrotic phase; this genotype clustering was less pronounced during the fibrotic phase and completely absent at the prenericotic stage. In addition, mdxTLR4−/− BMDM from both the necrotic (Fig. 5c) and fibrotic (Fig. 5d) stages exhibited a higher maximal OCR level compared to their age-matched mdx BMDM counterparts. Exposure to unrelated secondary stimuli (Fig. 5e–h) revealed that the expression of both pro-inflammatory and anti-inflammatory genes was reduced in mdxTLR4−/− BMDM in comparison to necrotic phase mdx BMDM. The changes in mRNA transcript levels were corroborated at the protein level by western blotting (Fig. 5i) and ELISA (Fig. 5j). Furthermore, using the same in vitro ME stimulation protocol which induced signs of trained immunity in WT BMDM (Fig. 4a) we found that this training response to ME was prevented in cultured BMDM from TLR4-deficient (non-dystrophic) mice. This was evinced by absence of the characteristic amplified gene expression responses to fibrinogen and β-glucan (Fig. 5k, l). Overall, these data indicate that the hyperresponsiveness to unrelated secondary inflammatory stimuli as well as the altered metabolic phenotype observed in mdx BMDM are largely abrogated by TLR4 deficiency.

**mdx BMDM are epigenetically altered in a TLR4-dependent manner.** Epigenetic reprogramming is an important mechanism underlying the development of trained immunity. We performed chromatin immunoprecipitation (ChIP)-seq to quantify tri-methylation of histone 3 lysine 27 (H3K27me3), a histone mark classically associated with gene silencing. Genome-wide analysis revealed a significant reduction of H3K27me3 signal intensity in mdx BMDM compared to WT BMDM; in contrast the mdxTLR4−/− BMDM showed an overall increase in H3K27me3 signal relative to WT (Fig. 6a). The three experimental groups were next analyzed according to their different patterns of relative H3K27me3 signal intensity in close proximity (−5 kb to +1 kb) to the gene body across the genome (see Supplementary Data 1 table). This analysis identified four distinct patterns (termed GP1–GP4) showing dynamic regulation in the mdx group relative to WT (Fig. 6b). Among the mdx-altered H3K27me3 peaks, by far the predominant pattern was a relative reduction of the signal in mdx compared to WT, with restoration to WT levels in the mdxTLR4−/− group (GP1 = 69% of peaks). This pattern was followed in frequency by a reduction in mdx without restoration in mdxTLR4−/− (GP2 = 24% of peaks); increase in mdx without restoration in mdxTLR4−/− (GP3 = 5% of peaks); and increase in mdx with restoration in mdxTLR4−/− (GP4 = 2% of peaks).

Pathway analysis was next applied to the mdx-altered H3K27me3 signal patterns using Reactome informatics (Supplementary Data 2 table). For the largely predominant GP1 pattern, extracellular matrix- and collagen-related processes were among the most significantly enriched biological pathways (Fig. 6c; see Supplementary Fig. 5 for GP2-4 patterns). Individual genes selected a priori to reflect key pro-inflammatory, anti-inflammatory, and pro-fibrotic processes were also examined (Supplementary Data 3 table). In comparison to the WT group, there was a widespread decrease of the H3K27me3 mark in mdx BMDM for all of these gene categories, which was significantly reversed in the mdxTLR4−/− group (Fig. 6d, e). Dynamically regulated patterns of the H3K27me3 mark in mdx BMDM were also used to perform
transcription factor-related pathway analysis (Supplementary Fig. 6). The latter analysis indicated that for the most frequently observed H3K27me3 pattern (termed PP1), transcription factor enrichment was found for genes linked to the VENTX homeobox protein, RUNX3/Wnt signaling, and several interleukins (IL-21, IL-35, IL-23, IL-20, IL-12, IL-2) (Supplementary Fig. 6; Supplementary Data 4 and 5 tables).

ChIP-qPCR was employed to corroborate these results by quantifying the H3K27me3 mark within promoter regions of the prototypical pro- and anti-inflammatory marker genes. In keeping with the ChIP-seq data, the mdx group showed lower H3K27me3 promoter occupancy than in WT (Fig. 6f), whereas levels of this histone mark were relatively increased in the mdx TLR4-/- group (Fig. 6g). ChIP-PCR was additionally utilized to assess promoter occupancy by H3K4me3 (Supplementary Fig. 7), a permissive histone mark typically associated with gene activation. Greater H3K4me3 promoter occupancy was observed for several genes in the mdx group (Supplementary Fig. 7a), but in contrast to H3K27me3, genetic abrogation of TLR4 in mdx BMDM had no significant impact on H3K4me3 deposition (Supplementary Fig. 7b).

In addition to changes in methylation, increased acetylation (ac) of H3K27 is linked to greater chromatin accessibility and increased transcriptional competency. ChIP-seq revealed that in comparison to WT BMDM, there was an overall reduction of H3K27ac signal intensity in mdx BMDM, with a further decrease in the mdx TLR4-/- group (Supplementary Fig. 8a, b; Supplementary Data 1 table). Reactome pathway analysis (Supplementary Data 2 table) of this dominant pattern (GP1 = 73% of peaks) indicated particular enrichment for biological processes associated with protein metabolism, the cell cycle, and gene expression (Supplementary Fig. 8c). The next most frequent pattern was increased H3K27ac signal in mdx BMDM compared to WT and a relative decrease in the mdx TLR4-/- group (GP2 = 16% of peaks). Interestingly, this pattern was especially enriched for cellular responses to stress and external stimuli.

**Fig. 4 BMDM exposed to muscle damage show a trained-like phenotype both in vitro and in vivo.** a Experimental design for WT- or mdx- muscle extract (ME) exposure to induce trained immunity in naïve WT BMDM. b, c Transcript levels are shown for BMDM trained with PBS, WT-ME, or mdx-ME and then secondarily exposed to fibrinogen (Fib) or RPMI for 8 h; the mRNA levels determined by qPCR are expressed relative to the mean control (PBS-trained and RPMI-stimulated) value (n = 5/group). d Schematic representation of the BM transplant chimeric model. At 11 weeks post-transplantation BMDM were generated from recipient mice previously transplanted with whole BM from either WT (WT → WT) or mdx (mdx → WT) mice at necrotic phase. The BMDM were stimulated with fibrinogen or β-glucan for 4 and 24 h (e–h); e (n = 4 for TNF in 24 h mdx group, rest n = 5/group), f (n = 5/group), g (n = 4 for TNF in 4 h mdx group, rest n = 5/group), h (n = 4 for TGFβ and CD206 WT 4 h groups, rest n = 5/group). Data represent means ± SEM of biologically independent samples from different mice, b, c *P < 0.05 vs. PBS-trained and †P < 0.05 vs. WT-ME trained. e–h *P < 0.05 vs. WT-unstimulated and †P < 0.05 vs. WT-stimulated group at a given time point (one-way ANOVA followed by a Tukey post-hoc test, two-tailed). See Source Data file for the exact P-values.
(Supplementary Fig. 8d), which is consistent with the trained immunity phenotype. Transcription factor-related pathway analysis was also performed (Supplementary Fig. 9; Supplementary Data 4 and 5 tables), and the corresponding peak patterns suggested possible involvement of interleukin, Notch, and interferon signaling.

Taken together, these data suggest a complex pattern of epigenetic reprogramming in mdx BMDM, with co-existence of histone mark modifications that can either augment (decreased H3K27me3 and increased H3K4me3) or reduce (decreased H3K27ac) the open chromatin state. The predominant histone mark changes demonstrated in mdxTLR4-/- BMDM, on the other hand, would generally be expected to decrease chromatin accessibility (increased H3K27me3 and decreased H3K27ac). In addition, among the epigenetic modifications observed in mdx BMDM, it was most clearly evident for H3K27me3 that the changes...
**Fig. 5** TLR4 regulates the altered phenotype of mdx BMDM. **a** Basal M1 and M2 marker gene transcript levels (expressed relative to the mean age-matched WT level) in BMDM from WT, mdx, mdxTLR4−/− mice at different phases of disease (n = 4 for iNOS in prenecrotic phase and IL12α in necrotic phase mdx groups, rest n = 5/group). **b** Heatmap showing unsupervised hierarchical clustering analysis of samples based on the gene expression data shown in **a**. Genes with higher and lower expression levels are identified as red or blue (variable units proportional to color intensity), respectively, whereas outlier samples are black. **c, d** Oxygen consumption rate (OCR) data for mdx and mdxTLR4−/− BMDM at necrotic (n = 5/group) and fibrotic phases (n = 5/group) of the disease. **e-h** WT, mdx, and mdxTLR4−/− BMDM at necrotic phase were stimulated with LPS + IFNγ (n = 5/group) or IL4 (n = 5/group) or fibrinogen (n = 3/group) to determine mRNA transcript levels (expressed relative to the mean WT-unstimulated value) of: (e, g) M1 and (f, h) M2 marker genes. **i** Western blot images and densitometric analyses of total iNOS and Arginase1 in cell lysates of fibrinogen-stimulated (24 h) WT, mdx, and mdxTLR4−/− BMDM from necrotic phase mice (n = 3/group; all experimental replicates are shown). **j** ELISA measurements of TNF and IL6 protein levels in culture supernatants from WT, mdx and mdxTLR4−/− BMDM after stimulation with fibrinogen for 24 h (n = 4/group). **k, l** As shown in Fig. 4a, WT and TLR4−/− BMDM were trained with mdx-ME and secondarily challenged with k fibrinogen (8 h; n = 4/group) or l β-glucan (4 h; n = 4/group), followed by qPCR. The graph shows mRNA transcript levels of genes relative to the mean control (PBS-trained and RPMI-stimulated) WT group. Data represent means ± SEM of biologically independent samples from different mice; *P < 0.05 WT vs. mdx and †P < 0.05 mdx vs. mdxTLR4−/− (one-way ANOVA followed by Tukey post-hoc test, two-tailed); c, d *P < 0.05 WT vs. mdx (unpaired t-test, two-tailed); e-j *P < 0.05 WT and †P < 0.05 vs. mdx at a given time point (one-way ANOVA followed by a Tukey post-hoc test, two-tailed); †P < 0.05 PBS vs. ME and ‡P < 0.05 WT vs. TLR4−/− group (two-way ANOVA followed by a Tukey post-hoc test, two-tailed). See Source Data file for the exact P-values.

**Fig. 6** Dynamic regulation of H3K27me3 is present in mdx BMDM and mediated by TLR4. ChIP sequencing was performed in WT, mdx and mdxTLR4−/− BMDM. **a** Violin plots representing normalized intensity fold-change (H3K27me3 vs. input) in the −5 kb to +1 kb neighboring genomic region around all genes across the whole genome; *P < 0.0001 compared to WT BMDM and †P < 0.0001 compared to mdx group (two-sided Mann–Whitney U-test). **b** Heatmaps showing, in order of frequency (indicated by the percentages in parentheses), the different Gene-based Patterns (GP1-4) of the normalized H3K27me3 read intensity (variable units proportional to red color intensity) within the nearby region [−5 kb to +1 kb] of the gene body for WT, mdx, and mdxTLR4−/− BMDM. **c** Pathway enrichment analysis (Reactome database) for genes showing the predominant GP1 configuration (Supplementary Data 2 table shows the extended list for all Gene-based Patterns). The vertical line indicates the cutoff P-value = 0.05. **d** Heatmaps of H3K27me3 intensity for pro-inflammatory, anti-inflammatory, and pro-fibrotic pathways (see Supplementary Data 3 table for complete gene lists). **e** Representative pro-inflammatory gene loci (iNOS, IL12α) showing the lower H3K27me3 peak intensity in the mdx group compared to WT and mdxTLR4−/−. **f, g** ChIP-qPCR was performed to detect H3K27me3 occupancy on the promoters of M1 and M2 marker genes in: f WT versus mdx BMDM (n = 4 for iNOS, IL12α, CD206 and Arg1) gene in mdx group, rest n = 5/group and g mdx versus mdxTLR4−/− BMDM (n = 5/group); IgG was used as a control for non-specific binding of antibody. Data represent means ± SEM of biologically independent samples from different mice: *P < 0.05 by unpaired t-test, two-tailed). See Source Data file for the exact P-values.

were TLR4-dependent and could promote increased transcriptional activation of genes involved in inflammation and fibrosis.

Functional differences between WT, mdx, and mdxTLR4−/− BMDM in vivo. Finally, to determine whether the changes in mdx BMDM phenotype in vitro are associated with functional differences in vivo, we performed inelavine-associated transfer of bone marrow from necrotic phase mdx mice or age-matched WT mouse (bone marrow donors) into WT recipient mice (hosts) subjected to acute hindlimb muscle injury via cardiototoxic injection (Fig. 7a). The bone marrow donor mice shared the
Fig. 7 Adoptive transfer reveals the altered phenotype of mdx and mdxTLR4−/− BMDM after muscle injury in vivo. a Pictorial representation showing adoptive transfer of bone marrow (BM) from WT or mdx (both CD45.2 allele) mice into non-irradiated congenic WT (CD45.1 allele) mice at the onset of cardiotoxin-induced hindlimb muscle injury, followed by flow cytometric analysis of donor and host BMDM in the injured muscle 4 days later. b–d Comparison of absolute number of: b Hematopoietic precursor cells (CLP: common lymphoid progenitors, CMP: common myeloid progenitors, GMP: granulocyte/macrophage progenitors, MEP: megakaryocyte/erythrocyte progenitors; n = 5/group), c Innate myeloid cells (EPs: Eosinophils, NPs: Neutrophils, MCs: Monocytes, MPs: Macrophages) (n = 5/group) and d Lymphocytes (B: B cells, CD3: CD3+ T cells, CD4: CD4+ T cells, CD8: CD8+ T cells) (n = 5/group) in the BM of age-matched WT or mdx at necrotic phase. e, f Quantification of host (CD45.1−WT; n = 15/group) and donor (CD45.2−either WT or mdx or mock adoptive transfer with PBS; f n = 14 for WT, rest n = 15/group) macrophages in the injured muscles (defined as CD45+CD11c−CD11b+F4/80+) and h donor anti-inflammatory (iNOS−TGFβ+CD206+) BMDM of either WT or mdx origin in the injured WT host muscle (n = 10/group). i Schematic showing adoptive transfer of mdx or mdxTLR4−/− BM using the same experimental design. j, k Quantification of host (CD45.1−WT; n = 6 for PBS, rest n = 10/group) and donor (CD45.2−either mdx or mdxTLR4−/−; n = 5/group) macrophages in the injured muscles. l Percentage of donor pro-inflammatory and m donor anti-inflammatory BMDM of either mdx or mdxTLR4−/− origin in the injured WT host muscle (n = 5/group). Data represent means ± SEM of biologically independent samples from different mice. *P < 0.05 (unpaired t-test, two-tailed). See Source Data file for the exact P-values.
common CD45.2 allele and both strains (WT and mdx) demonstrated an equivalent distribution of bone marrow leukocyte populations prior to adoptive transfer (Fig. 7b–d). The bone marrow recipient WT host mice had the CD45.1 allele in order to allow donor versus host origin macrophages to be distinguished by flow cytometry. Muscles were collected from the WT host mice at 4 days post-injury, which was the approximate time of maximal macrophage infiltration.

The majority of macrophages in the injured muscle were of host origin (CD45.1), and there were no differences in CD45.1 macrophage number between the WT and mdx donor groups (Fig. 7e). However, donor origin (CD45.2) BMDM in the injured muscles were significantly more abundant in the mice injected with mdx donor cells as compared to WT donors (Fig. 7f). As muscles of mdx mice from the necrotic phase of disease contain a higher proportion of pro-inflammatory (iNOS+, TGFβ-, CD206-) macrophages (Supplementary Fig. 10), we also sought this phenotypic signature in the adoptively transferred BMDM. In the host mice that received mdx bone marrow donor cells, the injured muscles contained a greater percentage of CD45.2 macrophages exhibiting a pro-inflammatory phenotype in comparison to mice which had received WT donor cells (Fig. 7g, b). Importantly, these differences in inflammatory profile were limited to the CD45.2 (donor) macrophages and not observed in CD45.1 (host) macrophages (Supplementary Fig. 11a, b) within the same muscles.

The same experimental design was used to compare the in vivo behavior of mdx versus mdxTLR4−/− bone marrow origin macrophages (Fig. 7i). Once again there were no differences in the numbers (Fig. 7j) or inflammatory profile (Supplementary Fig. 11c, d) of host origin (CD45.1) macrophages within the injured WT muscles. In contrast, adoptively transferred (CD45.2) macrophages were reduced in number (Fig. 7k) and also less inflammatory (Fig. 7l, m) in the injured WT muscles of mice that received mdxTLR4−/− donor cells as compared to the group injected with mdx donor cells. These in vivo adoptive transfer studies are in keeping with the earlier in vitro data and support the presence of an altered macrophage phenotype in mdx mice that is epigenetically imprinted at the level of the bone marrow and significantly mediated via TLR4.

Discussion

From an evolutionary standpoint, the immune system is primarily designed to deal with acute localized muscle damage (e.g., traumatic or infectious) rather than the ongoing widespread injury found in chronic muscle diseases such as DMD. After acute muscle injury an initial wave of bone marrow (monocyte)-derived M1-like macrophages populates the muscle, which are then replaced by macrophages with a M2-like phenotype. As a general rule, any interference with this tightly regulated sequence of events impedes normal skeletal muscle repair. Importantly, this normal sequence is lost in the context of DMD, where repeated injury leads not only to an abnormal persistence of macrophages, but also to a decreased prevalence of macrophages within the muscle that exhibit simultaneous upregulation of both M1 and M2 marker genes. Failed muscle regeneration and subsequent fibrosis in dystrophic muscle have been substantially attributed to dysregulated function of macrophages and other immune cells. The dystrophin isoform (Dp71) found in myeloid cells remains intact in the mdx mouse, and macrophage dysregulation is thought to be primarily driven by pathological cues received directly within the local muscle microenvironment. The results of the present study add a major new layer of complexity to this scenario by showing that before their entry into the pathological muscle microenvironment, BMDM of dystrophic mice undergo extensive epigenetic remodeling which is accompanied by pronounced alterations in cellular function.

The fact that a primary muscle disease induces such effects within bone marrow myeloid cells implies a role for systemic signaling molecules such as DAMPs originating from the damaged muscles. This concept is supported by the fact that muscle extract derived not only from mdx but also from healthy WT mice, was able to induce changes consistent with trained immunity within naive WT BMDM in vitro. However, the involvement of muscle damage-derived DAMPs as the primary stimulus generating trained immunity in mdx mice remains a hypothesis, and it is possible that other factors such as cytokines or exosomes play significant roles within the in vivo environment. Furthermore, it is interesting to note that the induction of acute necrotic muscle injury in WT mice in vivo, whether in either single or repeated bouts, did not recapitulate the changes observed in mdx BMDM. This is perhaps not surprising since the nature of the molecules released by different mechanisms of muscle damage, as well as the quantity and duration of exposure to DAMPs and other signals delivered to the bone marrow, may differ substantially for various forms of acute versus chronic muscle injury.

Several DAMPs are known to be endogenous ligands for TLR4. Among candidate DAMPs that are chronically increased in the muscles and/or serum of mdx mice and DMD patients, some such as fibrinogen have been directly implicated in DMD pathogenesis. The levels of such DAMPs can also vary according to disease stage, which may at least partially explain our observation of disease stage-specific differences in mdx BMDM characteristics. Genetic deficiency of fibrinogen led to reduced muscle pathology in mdx mice. Along the same lines, we previously reported that global TLR4 deficiency in mdx mice reduces pro-inflammatory macrophages within mdx muscles and significantly mitigates disease progression including in the most severely affected muscle, the diaphragm. This is consistent with the fact that low concentrations of TLR ligands induce CCR2-dependent monocyte emigration from the bone marrow. In the present study, we found that the phenotypic changes observed in mdx BMDM in vitro were all largely prevented in mdx mice lacking TLR4. Although this could be partially related to less severe muscle pathology in mdxTLR4−/− mice, our data indicate that the ability to induce trained immunity is also severely impaired in non-dystrophic BMDM lacking TLR4. In addition, adoptive transfer studies in vivo showed that the mdx BMDM recruited to injured muscles were significantly reduced in number and associated with a less inflammatory profile when these BMDM lacked TLR4.

In our study, mdx BMDM demonstrated an undifferentiated mixed M1/M2 phenotype in vitro, whereas mdx BMDM that were adoptively transferred into an inflammatory muscle injury milieu (such as found in early stages of the disease), exhibited pro-inflammatory M1-like skewing. The alterations in cellular metabolism observed over time in mdx BMDM, suggesting a greater reliance on oxidative phosphorylation at later stages of the disease, are consistent with the macrophage phenotype evolution from M1- to M2-like previously described within mdx muscles. We speculate that the epigenetic and metabolic reprogramming found in mdx BMDM serves to place the cells in a more conducive state for assuming different possible macrophage phenotypes after entering the muscle. According to this model (see Fig. 8), the functional modifications taking place centrally in the bone marrow favor more efficient adoption of either end (or some combination thereof) of the M1/M2 polarization spectrum. The ultimate phenotypic outcome peripherally in the dystrophic muscle tissue is determined by additional factors, such as the specific nature of the inflammatory milieu.
trained immunity induced by $\beta$ skewing toward M1 or M2 subtypes, which is also observed in phages suggested global activation of the cells rather than simple receptors. Analysis of classical markers for M1 and M2 macrophages to adopt different phenotypes once the cells home to damaged dystrophic muscle tissue. The ultimate macrophage functional phenotype and impact (adaptive or maladaptive) are dependent on the combination of signals received at the bone marrow level and within the dystrophic muscle milieu.

signals received within the local muscle microenvironment. This scenario is analogous to the epigenetically-mediated “poised” state of embryonic stem cells, where a mixture of activating and repressive marks on the same histones helps to maintain pluripotency until further environmental cues are received to drive differentiation toward a specific lineage.

Trained immunity is an evolutionarily conserved protective response against infection that first arose in organisms without an adaptive immune system such as plants and invertebrates. In addition to epigenetic changes, we found that mdx BMDM demonstrated several other keystone features of trained immunity. A major hallmark is the ability to invoke a more intense inflammatory response upon re-challenge not only with the initial triggering stimulus, but also with other agents that differ from the initial challenge stimulus. This is thought to result from the fact that a more open chromatin state induced by the epigenetic alterations permits a relatively broad and non-specific increase in transcription factor accessibility to the regulatory elements of innate immune system genes. Along these lines, mdx BMDM demonstrated increased cytokine responses to a wide range of heterologous stimuli (cytokines, fibrinogen, $\beta$-glucan) despite the reliance of these diverse stimuli upon different cell surface receptors. Analysis of classical markers for M1 and M2 macrophages suggested global activation of the cells rather than simple skewing toward M1 or M2 subtypes, which is also observed in trained immunity induced by $\beta$-glucan. The above characteristics were found in mdx BMDM despite removal of the cells from their in vivo environment for 1 week, a “rest period” previously used to demonstrate trained innate immunity in cultured human monocytes. Remarkably, long-lasting differences between WT and mdx BMDM were also transmissible in vivo, being maintained for at least 11 weeks after removal from the inducing muscular dystrophy environment by transplanting the mdx bone marrow into healthy WT mice.

Epigenetic changes representing a form of imprinted cellular memory or education have increasingly been implicated in the pathogenesis of inflammatory diseases. In some cases the maintenance of inflammation at an abnormally high basal level is sustained for a prolonged period after removal of the activating stimulus, which has been referred to as priming. In other instances, removal of the inciting stimulus allows innate immune system activity to largely return to its original low basal state, but upon reintroduction of either the same or unrelated immunological stimuli there is a more robust transcriptional response. The latter situation is characteristic of trained immunity and was found to be the case in mdx BMDM. The most commonly reported epigenetic changes linked to trained immunity in prior studies have involved histone modifications such as H3K4 methylation and H3K27 acetylation. In addition, it was recently shown that TLR4 signaling triggered by transient LPS exposure can induce persistent alterations of myeloid enhancer accessibility within hematopoietic stem cells, accompanied by improved innate immunity against infection.

In the present study, we show that mdx BMDM exhibit a complex combination of histone mark modifications that can simultaneously favor or impede the open chromatin state. These findings are similar to a previous report also showing a simultaneous decrease in repressive and activating histone marks in trained immunity, which could serve to maintain gene transcription in a poised state. It is also important to note that epigenetic modifications in mdx BMDM undoubtedly extend well beyond the changes found in our study. However, at least with respect to H3K27, it appears that increased chromatin accessibility in mdx BMDM is primarily mediated through reduced methylation rather than increased acetylation. Furthermore, the changes in H3K27me3 were TLR4-dependent and involved genes associated with dystrophic muscle inflammation and fibrosis.

Current evidence suggests that trained immunity can occur in humans, where it may be an important driver of pathological inflammation in non-infectious diseases such as atherosclerosis, Alzheimer’s disease and chronic allergy. To our knowledge the present study provides the first evidence for trained immunity in DMD or any other form of skeletal muscle disease. These findings suggest the possibility of a new paradigm for DMD muscle inflammation in which monocyte-derived macrophages from the bone marrow undergo a process of extensive cellular

Fig. 8 Model for cross-talk between dystrophic skeletal muscle and bone marrow leading to a reprogrammed macrophage phenotype. According to the model, chronic systemic exposure to damage-associated molecular patterns (DAMPs) acting as ligands for innate immune receptors such as TLR4, induces the hallmark features of trained immunity (cytokine hyperresponsiveness, metabolic alterations, epigenetic rewiring) in macrophage precursor cells residing in the bone marrow. A more open chromatin state for both pro-inflammatory and anti-inflammatory genes enhances the ability of future macrophages to adopt different phenotypes once the cells home to damaged dystrophic muscle tissue. The ultimate macrophage functional phenotype and impact (adaptive or maladaptive) are dependent on the combination of signals received at the bone marrow level and within the dystrophic muscle milieu.
reprogramming before being recruited to the diseased muscles. This altered myeloid cell phenotype is regulated by TLR4 and displays the features of: (1) increased constitutive and DAMP-stimulated cytokine production, (2) changes in cellular metabolism, and (3) epigenetic remodeling. While these results are consistent with altered innate immune memory in murine DMD, whether these phenomena also occur in human DMD or other types of chronic muscle disease remains to be determined. The mdx model of DMD exhibits a more intense phase of early necrosis than human patients. In addition, the specific stimuli involved in the reprogramming of these cells are yet to be elucidated. Future studies should be directed at determining whether either preventing or reversing these processes is feasible and able to favorably modify the course of the disease. It will also be of interest to ascertain whether trained immunity, through amplification of the host immune response, represents an impediment to gene therapy and other dystrophin restoration strategies.

**Methods**

**Experimental animals.** All procedures were approved by the Animal Care and Use Committee of Research Institute of the McGill University Health Centre (RI-MUHC, protocol #3480), according to the guidelines issued by the Canadian Council on Animal Care. Wild-type (WT) mice: CD45.2 (stock #000664) and CD45.1 (stock #002014) alleles, dystrophic mdx<sup>51</sup> mice (mdx, stock #002578) and TLR4<sup>−/−</sup> mice (stock #029015) were on the C57BL/6 J background, with all breeding pairs originally purchased from The Jackson Laboratories (Bar Harbor, ME). The mdx mice lacking TLR4 (mdxTLR4<sup>−/−</sup>) were generated as described previously<sup>12</sup>. All experiments were performed on male mice. Both experimental and control groups were bred separately and co-housed under pathogen-free conditions at the animal facility of RI-MUHC and kept under a 12 h light/12 h dark cycle at a temperature 21 ± 1 °C and relative humidity of 40–60%. Euthanasia was conducted under anesthesia with isoflurane followed by cervical dislocation.

**Culture of bone marrow-derived macrophages (BMDM).** L929 mouse fibroblast cells were purchased from the American Type Culture Collection and grown at 37 °C with 5% CO<sub>2</sub> for 7 days in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS); supernatant containing macrophages colony-stimulating factor (M-CSF) was then collected and stored at −80 °C for later use. For BMDM culture, tibia and femur bone were harvested bilaterally and bone marrow was flushed out using a syringe filled with Roswell Park Memorial Institute (RPMI) (Wisent) medium containing 10% FBS. Bone marrow cells were plated in RPMI media supplemented with 2 mM l-glutamine, 10% FBS, 1% non-essential amino acids, 1% essential amino acids, 0.14% 5 N NaOH, 2% HEPES, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin (all from Wisent) and 30% L929 supernatant for 7 days in order to stimulate cytokine production, (2) changes in cellular metabolism (Seahorse) analyses

**Generation of bone marrow chimeric mice.** C57BL/6 CD45.1 (Jackson Laboratory, USA) recipient mice (6 weeks of age) were lethally irradiated with total 12 Gy (delivered with two doses of 6 Gy at 4 h apart) (X-RAD Smart, Precision X-ray, North Branford, CT). At 24 h after the second dose of radiation, 4 x 10<sup>6</sup> bone marrow cells isolated from either WT or mdx (donor, CD45.2 mice) were injected intravenously to recipient mice. Mice were given antibiotic treatment (50 mg/ml enrofloxacin, Bayer, USA) in drinking water for three days before and after irradiation. Bone marrow chimerism was determined by flow cytometry 11 weeks after transplantation.

**Bone marrow adaptive transfer and acute muscle injury.** For adoptive transfer experiments, bone marrow of CD45.2 aliene donor mice (WT, mdx or mdxTLR4<sup>−/−</sup>) was isolated and 6 x 10<sup>6</sup> cells in PBS were injected intravenously into CD45.1 aliene host recipient mice immediately prior to induction of muscle injury. To induce acute skeletal muscle injury, both hindlimbs (tibialis anterior (TA) muscle) were injected with 25 µl of 10 µM cardiotxin as previously described<sup>2</sup>. Four days later the TA muscles of mice were euthanized and muscle samples were collected and fixed in 10% aqueous formaldehyde (FA) for 24 h before paraffin-embedding, and then sectioned (5 µm) and stained with hematoxylin and eosin (H&E) for histological analysis and determination of injury severity (1-6) on a blinded fashion. Tissue areas were measured using publically available Hematoxylin and Eosin Scoring software (HES software, National Institute on Aging, USA) and the injury score was defined as the percentage of the area of interest that had muscle fibers with necrotic nuclei.
Flow cytometry. Single cell suspensions were obtained by incubating minced muscles in 0.2% collagenase (Roche) at 37 °C for 45 min followed by filtering with a 70-μm cell strainer. The resulting muscle was fragmented in 2 ml of PKH67-phalloidin labeled PBS and passed through 70-μm cell strainer. For flow cytometry, 10^6 cells were resuspended in PBS containing 0.5% BSA (FACS buffer). To distinguish between live and dead cells, cells were stained with AF700 viability dye (Thermo Fisher Scientific, USA) and 0.1% PI for 30 min at 4 °C. The cells were then blocked with Fc blocking solution (anti-CD16/CD32, BD Biosciences) for 10 min followed by fluorescent-labeled antibody staining for 30 min at 4 °C.

Antibodies for flow cytometry were used at 1:100 dilution (BD Biosciences, USA) unless stated otherwise. For cell surface markers, the cells were stained in the dark with primary antibodies: PE-labeled anti-CD45.1 (clone A20), V500 labeled anti-CD45.2 (clone 104), BUV395 labeled anti-CD45.2 (clone 104), BV421 labeled anti-CD11c (1:5 dilution, clone HL3), APC-Cy7 labeled anti-CD11b (clone M1/70, BioLegend), PE-Cy7 labeled anti-4F8 (clone BM8, BioLegend), biotin conjugated: CD3 (clone 53-73, BioLegend), anti-Ly6G/C (clone RB6-8C5, BioLegend), anti-CD11b (clone M1/70), anti-CD4 (clone RM4-5), anti-CD8a (clone 53-67), anti-CD45R (clone RA3-6B2), Streptavidin conjugated APC-Cy7, BUV785 labeled anti-CD127 (clone A7R34), PE-Cy7 labeled anti-Sca-1 (clone D7, BioLegend), APC labeled anti-CD4 (clone 38F5, BioLegend), APC labeled anti-CD90 (clone 6G8, BioLegend), PE-PEF94 labeled anti-Siglec-F (clone E50-2440). After staining, cells were washed three times with FACS buffer followed by fixation with 4% PFA. For the staining of intracellular markers, cells were permeabilized with permeabilization buffer (Invitrogen, USA) and stained with antibodies in the permeabilization buffer at 4 °C in the dark.

For intracellular markers, cells were fixed with 4% PFA. For the staining of intracellular markers, cells were permeabilized with permeabilization buffer (Invitrogen, USA) and stained with antibodies in the permeabilization buffer at 4 °C in the dark. For the staining of intracellular markers, cells were permeabilized with permeabilization buffer (Invitrogen, USA) and stained with antibodies in the permeabilization buffer at 4 °C in the dark. For the staining of intracellular markers, cells were permeabilized with permeabilization buffer (Invitrogen, USA) and stained with antibodies in the permeabilization buffer at 4 °C in the dark.

Chromatin immunoprecipitation (ChIP)-qPCR

Chromatin immunoprecipitation (ChIP)-qPCR was performed as previously reported. Cultured BM/DM were washed twice with cold PBS and cells were non-enzymatically detached from the plate using “CellStripper” Dissociation Reagent (Corning, USA). Cells were washed three times with cold PBS and 5 x 10^6 cells were then resuspended in douncing buffer (10 mM Tris-HCl, pH 7.5, 4 mM MgCl2, 1 mM CaCl2, and 1 mM ethylenediaminetetraacetic acid (EDTA) and once with 80% ethanol and air-dried for 10 min before elution in 15 μl ddH2O. DNA Tailing was performed by incubating DNA at 37 °C for 30 min in the solution of 10.8 μg/ml DNA ligase II (New England Biolabs, Canada) at 37 °C for 7 min, and the reaction was inactivated with 4% PFA. For the staining of intracellular markers, cells were permeabilized with permeabilization buffer (Invitrogen, USA) and stained with antibodies in the permeabilization buffer at 4 °C in the dark.

Library preparation for ChIP sequencing

Library preparation for ChIP sequencing. For library preparation, ChIP DNA ends were first repaired at 20 °C for 30 min with repair buffer (2.9 μl of H2O, 0.5 μl 1% Tween-20, 1 μl dNTP mix 10 mM (dCTP, dGTP, dATP, dTTP), 5 μl 10x ligase buffer (New England Biolabs, USA), 0.2 μl of T4 DNA polymerase (New England Biolabs, USA), 0.2 μl of MnCl2 (New England Biolabs, USA), 0.03 μl PK fixes for 10 min. Beads were washed twice with 80% ethanol and air-dried for 10 min before elution in 15 μl ddH2O. DNA Tailing was performed by incubating DNA at 37 °C for 30 min in the solution of 10.8 μg/ml DNA ligase II (New England Biolabs, Canada) at 37 °C for 7 min, and the reaction was inactivated with 4% PFA. For the staining of intracellular markers, cells were permeabilized with permeabilization buffer (Invitrogen, USA) and stained with antibodies in the permeabilization buffer at 4 °C in the dark.

ChIP-seq data analysis

ChIP-seq data analysis. All H3K27me3 reads for the three libraries (WT, mdx, mdxTLR4^-/-) were first mapped to the mm10 genome using Bowtie2 under the default parameters. There were four samples for each of the libraries (H3K27me3 replicate 1, H3K27me3 replicate 2, Input replicate 1, Input replicate 2). The reads from replications were merged for the downstream analyses. With the merged reads, we quantified the read intensity for both the H3K27me3 and Input sample of each library using deepTools. The peak calling was followed by deepTools enuP (the default parameters) (window size = 200, gap size = 600). All peaks with FDR < 0.01 were kept as the final significant peaks. The overlapped genes were merged and finally 35,918 significant peaks for WT, mdx, and mdxTLR4^-/- were identified.

After all the peaks and genome-wide read intensities for the three libraries were acquired, different methylation patterns for these peaks were assigned. We first determined whether there was a significant methylation difference (H3K27me3 vs. Input) associated with the peak region for each of the libraries. The significance was calculated based on the read intensity difference between the H3K27me3 and Input data using a one-sided Mann–Whitney U test. If the H3K27me3 read intensity was significantly higher (defined as P-value < 0.05 and intensity fold-change > 1.5) than its corresponding input, the peak was designated as Increased (I); otherwise, the peak was designated as Unchanged (U). The obtained significant peaks were assigned to 2 (2') different patterns for WT, mdx, and mdxTLR4^-/- libraries included in this study. After inferring the pattern for a specific peak relative to the input, we also required that the methylation intensity fold-change of the peak in any “Increased” (I) library be statistically greater than that in any “Unchanged” (U) library (Mann–Whitney U test, P-value < 0.05). The associated genes were identified for these significant peaks if located within ~5 kb to +1 kb of the gene.

Besides the above analysis strategy, the patterns for all genes across the genome were also directly evaluated as follows. If the methylation read intensity in the nearby region (~5 kb to +1 kb relative to the gene body) was significantly greater in the H3K27me3 sample than its corresponding Input, this gene was designated as Increased (I). Otherwise, it was considered as Unchanged (U). The obtained significant peaks were assigned to 2 (2') different patterns for WT, mdx, and mdxTLR4^-/- libraries included in this study. After inferring the pattern for a specific peak relative to the input, we also required that the methylation intensity fold-change of the peak in any “Increased” (I) library be statistically greater than that in any “Unchanged” (U) library (Mann–Whitney U test, P-value < 0.05). The associated genes were identified for these significant peaks if located within ~5 kb to +1 kb of the gene.

To assess whether a given list of genes was statistically enriched with a particular pattern, we used the binomial test as follows. First, we calculated a background probability p_i(n) for each pattern n, which is the percentage of genes (out of all genes) that follow that particular pattern. The enrichment P-value can be calculated using the following Eq. 1:

\[ P_value(p_i) = 1 - \sum_{n=1}^{k} \binom{n}{i} p_i(n) \left(1 - p_i(n)\right)^{n-i}, \]

where \(n\) is the total number of genes in the gene list of interest, and \(k\) is the number of genes that follow the pattern (n) under the null hypothesis H0: more than \(k\) out of \(n\) genes follow the pt pattern randomly. The biological pathways enriched with the above patterns were determined using the Reactome pathway database, with a particular focus on those four patterns showing dynamic regulation in WT vs. mdx groups (GP1–GP4). Using this approach, we defined the Gene-based Pattern (GP) analysis, identified 3299 genes with 4 distinct patterns (designated GP1 to GP4 = I1, I2, I3, I4) and their associated patterns included the two libraries. This analysis allowed the application of the biological pathway enrichment analysis (see below) for any given list of genes (e.g., genes from a particular pathway).

In addition, Hypergeometric Optimization of Motif EnRichment (HOMER)-2 software was employed to identify potential transcription factor enrichment within the peak regions exhibiting dynamic differences between the WT and mdx groups. Using an analogous approach to the Gene-based Pattern analysis outlined earlier, this was designated as a Peak-based Pattern (PP) analysis (PP1 to PP4). Using this approach, we defined the Peak-based Pattern analysis (sorted by the binomial test P-value) associated with each of these patterns (both peak-based and gene-based) was obtained.

In addition, Hypergeometric Optimization of Motif EnRichment (HOMER)-2 software was employed to identify potential transcription factor enrichment within the peak regions exhibiting dynamic differences between the WT and mdx groups. Using an analogous approach to the Gene-based Pattern analysis outlined earlier, this was designated as a Peak-based Pattern (PP) analysis (PP1 to PP4). Using this approach, we defined the Peak-based Pattern analysis (sorted by the binomial test P-value) associated with each of these patterns (both peak-based and gene-based) was obtained.
Comparisons between two groups were determined by unpaired t-test to adjust for multiple comparisons. Outliers identified by the software were excluded from the analysis. Error bars represent standard error of the mean (SEM) for the indicated number of observations. The "n" for each bar graph represents the number of independent biological replicates. For each figure, the statistical test used and number of observations are shown in the graph and respective figure legend. Exact P-values for each individual group comparison are provided in the Source Data file.

**Data availability**

The primary data which support the findings of this study are available in the Source Data file accompanying the paper. ChiP-seq data have been deposited in the Gene Expression Omnibus database under accession number GSE190307. We also provide a data server to enable interactive queries of the H3K27me3 status for any gene list (https://junding.lab.mcgill.ca/research/basil/H3K27ac/EnrichmentServer/). Similarly, a webserver for interactive exploration of H3K27ac status is also provided (https://junding.lab.mcgill.ca/research/basil/H3K27ae/EnrichmentServer/). Source data are provided with this paper.

Received: 2 February 2021; Accepted: 26 January 2022;
Published online: 15 February 2022

**References**

1. Duan, D., Goemans, N., Takeda, S., Mercuri, E. & Aartsma-Rus, A. Duchenne muscular dystrophy. *Nat. Rev. Dis. Prim.* 7, 13 (2021).
2. Hoffman, E. P., Brown, R. H. Jr & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell* 51, 919–928 (1987).
3. Petrof, B. J., Shragger, J. B., Stedman, H. H., Kelly, A. M. & Sweeney, H. L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. *Nat. Protoc. Sci. Acta. USA* 90, 3710–3714 (1993).
4. Rosenberg, A. S. et al. Immune-mediated pathology in Duchenne muscular dystrophy. *Sci. Transl. Med.* 299rv294 (2015).
5. Henriques-Pons, A. et al. Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle. *Hum. Mol. Genet.* 23, 2694–2677 (2014).
6. Wehling, M., Spencer, M. J. & Tidball, J. G. A nitric oxide synthase transgene induces inflammatory macrophages and controls inflammation in Duchenne muscular dystrophy. *Cell Rep.* 25, 2163–2176 (2018).
7. Mojumdar, K. et al. Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2. *EMBO Mol. Med.* 6, 1476–1492 (2014).
8. Serbina, N. V. & Pamer, E. G. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. *Nat. Immunol.* 7, 311–317 (2006).
9. Giordano, C. et al. Toll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophy. *Hum. Mol. Genet.* 24, 2147–2162 (2015).
10. Ma, J. et al. Transcriptome network analysis reveals a spectrum model for human macrophage polarization. *Immunity* 40, 274–288 (2014).
11. Gong, T., Liu, L., Jiang, W. & Zhou, R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. *Nat. Rev. Immunol.* 20, 95–112 (2020).
12. Foster, S. L., Hargreaves, D. C. & Medzhitov, R. Gene-specific control of inflammation byTLR-induced chromatin modifications. *Nature* 447, 972–978 (2007).
13. Netea, M. G., Schlitzer, A., Placek, K., Joosten, L. A. B. & Schultz, L. J. Innate and adaptive immune memory: an evolutionary continuum in the host’s response to pathogens. *Cell Host Microbe* 25, 13–26 (2019).
14. Divangahi, M. et al. Trained immunity, tolerance, priming and differentiation: distinct immunological processes. *Nat. Immunol.* 22, 2–6 (2021).
15. Li, J. et al. The nature of trained immunity. *Cell Host Microbe* 12, 223–232 (2012).
16. Novakovic, B. et al. Beta-glucan reverses the proinflammatory state of LPS-induced mononuclear cells. *Cell Rep.* 16, 1535–1546 (2016).
17. Bekkering, S. et al. In vitro experimental model of trained innate immunity in human primary monocytes. *Clin. Vaccin. Immunol.* 23, 926–933 (2016).
18. van der Heijden, C. et al. Epigenetics and trained immunity. *Antioxid. Redox Signal* 29, 1023–1040 (2018).
19. Bekkering, S. et al. Incomplete cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo. *Atherosclerosis* 254, 228–236 (2016).

**ARTICLE**

**NATURE COMMUNICATIONS** | https://doi.org/10.1038/s41467-022-28531-1 | www.nature.com/naturecommunications
Acknowledgements

This work was supported by the Canadian Institutes of Health Research (FRN 148744 to B.J.P.) and the JT Costello Memorial Fund of the Meakins-Christie Laboratories. We thank Dr. Carol CL Chen from Department of Human Genetics, McGill University for kind assistance with ChIP-qPCR experiments.

Author contributions

B.J.P. conceived and directed the project. S.B., Q.L., F.L., E.G., G.J.F., J.D., and E.K. developed methods and/or performed experiments. S.B., Q.L., O.L., G.J.F., E.K., and J.D. performed data analysis. S.B., M.D., J.D., and B.J.P. developed experimental concepts. S.B., J.D., and B.J.P. wrote the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-28531-1.

Correspondence and requests for materials should be addressed to Basil J. Petrof.

Peer review information Nature Communications thanks Niels P. Riksen, Yutaka Suzuki and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022